Literature DB >> 12837675

Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease.

Ching-ju Lu1, Larry E Tune.   

Abstract

OBJECTIVE: Authors examined the effect of chronic exposure to anticholinergics in a cohort of Alzheimer disease (AD) patients.
METHODS: All patients were examined annually with standard neuropsychologic tests and received the cholinesterase inhibitor donepezil hydrochloride at a dose of 10 mg/day. The study population (N=69) was divided into two groups: those receiving one or more concomitant medications with significant anticholinergic properties (N=16) and those receiving no concomitant medications with anticholinergic properties (N=53).
RESULTS: At 2 years, MMSE scores were significantly worse for patients receiving anticholinergic medications than for those not on anticholinergics.
CONCLUSION: Although very preliminary, these data suggest that concomitant therapy with anticholinergics may be associated with significant deleterious effects on acetylcholinesterase therapy, or, more speculatively, that chronic exposure to anticholinergics may have adverse effects on the clinical course of AD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12837675

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  25 in total

1.  Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.

Authors:  Edeltraut Kröger; Rob van Marum; Patrick Souverein; Toine Egberts
Journal:  Drugs Aging       Date:  2010-08-01       Impact factor: 3.923

2.  The relationship between anticholinergic medications and Mini-Cog scores in older adults receiving home health care.

Authors:  Susan L Lakey; Peggy S Odegard; Travis E Sonnett; Stephen M Setter; Soo Borson
Journal:  Consult Pharm       Date:  2009-09

3.  Concurrent use of anticholinergic drugs and cholinesterase inhibitors: register-based study of over 700,000 elderly patients.

Authors:  Kristina Johnell; Johan Fastbom
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

4.  Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French PharmacoVigilance Database.

Authors:  François Montastruc; Sarah Rouanet; Virginie Gardette; Vanessa Rousseau; Haleh Bagheri; Jean-Louis Montastruc
Journal:  Eur J Clin Pharmacol       Date:  2015-05-21       Impact factor: 2.953

5.  Central Anticholinergic Adverse Effects and Their Measurement.

Authors:  Pasi Lampela; Teemu Paajanen; Sirpa Hartikainen; Risto Huupponen
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

6.  Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes.

Authors:  Kaycee M Sink; Joseph Thomas; Huiping Xu; Bruce Craig; Steven Kritchevsky; Laura P Sands
Journal:  J Am Geriatr Soc       Date:  2008-04-01       Impact factor: 5.562

Review 7.  Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults.

Authors:  Daniel M I Britt; Gregory S Day
Journal:  Mo Med       Date:  2016 May-Jun

8.  Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia.

Authors:  Jessica A Wojtalik; Shaun M Eack; Bruce G Pollock; Matcheri S Keshavan
Journal:  Psychiatry Res       Date:  2012-11-15       Impact factor: 3.222

9.  Progress update: Pharmacological treatment of Alzheimer's disease.

Authors:  David B Hogan
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

Review 10.  The cognitive impact of anticholinergics: a clinical review.

Authors:  Noll Campbell; Malaz Boustani; Tony Limbil; Carol Ott; Chris Fox; Ian Maidment; Cathy C Schubert; Stephanie Munger; Donna Fick; David Miller; Rajesh Gulati
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.